Articles tagged with Liver Cancer
Researchers develop AI models to identify and classify blood cancers, achieving 99.5% sensitivity and 90.9% positive predictive value. An open-source platform, Turnkey Precision Oncology, helps molecular pathologists interpret genetic sequencing data and generate clinical reports with high accuracy.
A University of Houston researcher is developing a light-based technology to analyze tiny particles in the blood for molecular signs of liver cancer. The approach aims to detect the disease at its earliest stages and improve treatment options.
A study identified a vulnerability in liver cancer cells that depends on the combined action of CDK16 and CDK18 to repair DNA and multiply. Eliminating both proteins removes protection, leading to damage accumulation and cell death.
Dr. El-Khoueiry is an international leader in liver cancer treatment and clinical trials. He will advance USC Norris' mission to translate scientific discoveries into new cancer prevention, diagnosis, and treatment approaches.
Researchers at RIKEN have developed a synthetic compound that uses excess carbon monoxide produced by cancer cells to trigger the production of anti-cancer drugs within the cells themselves. The compound selectively targets tumors and avoids harming healthy cells, offering a promising new approach to cancer treatment.
A new review examines how gut microbiota and metabolites reshape liver immunity and propose strategies to overcome immunotherapy resistance. The review discusses four major directions of gut microbiota intervention, including probiotics, fecal microbiota transplantation, engineered bacteria, and metabolite-based interventions.
A new study suggests that routine liver cancer screening can be cost-effective and life-extending for individuals with alcohol-associated cirrhosis, even at low annual risk levels. The study found that biannual screening can generate significant life-years among both active drinkers and abstinent patients.
Researchers systematically summarize how epigenetic modifications and metabolic reprogramming interact to drive hepatocellular carcinoma. The review highlights the epigenetic-metabolism axis as a promising therapeutic target and offers new insights for treatment.
Researchers propose recognizing recompensation as a distinct treatment-related disease state, distinguishing stable and unstable recovery, to better capture recovery and continuing risks after cirrhosis treatment. This framework could support more consistent research, clinical assessment, and long-term surveillance for patients recover...
Japan has seen substantial reductions in HBV- and HCV-related disease burden and hepatocellular carcinoma mortality thanks to sustained national control measures. The prevalence of HBV and HCV has fallen drastically across Japan, with a significant shift in the relative distribution of liver cancer causes.
A new study finds that interventional radiologists (IRs) treat nearly 51% of Medicare patients with liver cancer, with the volume increasing over time. IRs deliver high-quality, high-impact care at a lower cost than oncologists, with faster recovery times and reduced hospital stays.
The FDA has approved daraxonrasib, a targeted therapy, based on a global clinical trial. Patients who took daraxonrasib lived almost twice as long as those receiving chemotherapy. Meanwhile, a grant from the Pancreatic Cancer Action Network aims to establish a blood test for pancreatic cancer using circulating tumor DNA.
The NRG Oncology trial found that proton therapy did not improve overall survival or progression-free survival for patients with advanced hepatocellular carcinoma. However, fewer grade 3 or higher treatment-related adverse events were observed with proton therapy compared to photon therapy.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
UCLA researchers present new radiotherapy research for prostate cancer, head and neck cancers, and personalized radiation therapy. A genetic test identifies men with prostate cancer at higher risk of urinary side effects after SBRT, suggesting personalized radiation treatment.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
Research identifies MLKL as a protein that helps drive liver cancer associated with obesity-related fatty liver disease by reducing mitochondrial function, promoting tumor development. Removing MLKL reduces liver tumors but not fatty liver or liver inflammation, suggesting a new therapeutic target for liver cancer treatment
Scientists have identified a pathway in liver cells that may explain how statins could help prevent or slow the development of liver cancer associated with fatty liver disease. Statins reduced levels of GGPP, a molecule that helps activate Rho GTPases, proteins involved in regulating a cell's internal structure and signaling.
Researchers at the University of Gothenburg identified a link between specific gut bacteria activities and primary sclerosing cholangitis, a rare chronic liver disease. Elevated levels of the metabolite ImP, formed by gut bacteria breakdown, can predict poorer survival outcomes and induce liver inflammation in PSC patients.
Researchers at the University of Basel have developed new drug combinations for liver cancer using mini-tumors, which retained key characteristics of the original tumor. The study identified several potent anti-tumor effects and combination therapies that could be effective despite significant biological differences between tumors.
Researchers analyzed data from 1,691 Australians with liver-spreading bowel cancer, finding younger patients had distinct tumour characteristics and lived longer after treatment. Genetic mutations such as BRAF and KRAS were associated with poorer outcomes across both age groups, highlighting the importance of genetic testing.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
A Singapore team developed a machine-learning tool that accurately predicts liver cancer recurrence after surgery, outperforming the TNM staging system. The tool identifies two biologically distinct patterns of recurrence, enabling personalized approaches to risk prediction and targeted therapies.
A study found that a TERT genetic variant may reduce the risk of developing cholangiocarcinoma, but be associated with worse outcomes in cancer patients. The variant was linked to improved overall survival rates before diagnosis, but poorer survival rates after diagnosis.
A study published in Cancer Cell identified a six-gene signature in microscopic colorectal cancer liver metastases that may help predict recurrence after treatment. The findings suggest these tiny tumor deposits could serve as a tissue-based marker of residual cancer cells, recurrence risk and chemotherapy resistance.
Combined hepatocellular-cholangiocarcinoma is a rare and aggressive form of primary liver cancer that poses significant diagnostic and therapeutic challenges. The absence of standardized treatment guidelines limits effective management, emphasizing the need for thorough pathological evaluation and multidisciplinary management.
A study published in JAMA Network Open found that high consumption of sugar-sweetened beverages was linked to an increased risk of liver cancer. In contrast, artificially sweetened beverage intake showed no significant association with liver cancer risk.
Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.
UCLA researchers are developing an AI-enhanced imaging platform to improve yttrium-90 radioembolization planning for patients with liver cancer. The new approach uses dynamic contrast-enhanced MRI scans to better characterize tumor blood flow and predict microsphere distribution.
The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
A phase 2 clinical trial found that 65% of patients receiving avatrombopag met key treatment goals, compared to 17% of those receiving placebo treatment. The oral medication has been shown to be effective in maintaining platelet counts needed to continue chemotherapy as scheduled.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Researchers found that restoring a young microbiome can reverse features of aging in the liver, including inflammation and DNA damage. The study suggests that a healthy gut microbiome plays a key role in preventing liver cancer.
Immune checkpoint inhibitors can cause immune-related hepatotoxicity, which is associated with female sex, younger age, Asian ethnicity, chronic liver disease, specific cancers, dual ICI therapy, and concurrent hepatotoxic drugs. Promising biomarkers include blood cell counts, CRP, autoantibodies, cytokines, SNPs, HLA types, and gut mi...
Researchers developed a cancer assessment tool that can identify high-risk patients and specific cell populations linked to their risk. The tool, called scSurvival, predicts survival outcomes more accurately than traditional methods by analyzing single-cell data at cellular resolution.
Researchers developed an AI model called Path-IO that uses machine learning to predict responses to immunotherapy for patients with metastatic non-small cell lung cancer. The model accurately stratified patients into high-risk and low-risk groups, with patients in the high-risk group having double the risk of death or disease progression.
The study provides a roadmap for understanding and treating liver cancer by identifying key biological processes that enable tumors to grow and spread. It highlights the potential for precision medicine approaches, including immunotherapy and targeted therapies, to improve outcomes for patients with liver cancer.
The study reveals that metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a major contributor to liver cancer worldwide and in China. Researchers call for integrated global prevention and early detection strategies to address this growing burden.
A study by IRB Barcelona researchers sheds light on the regulation of protein production in fatty liver cells, revealing a key role for CPEB4 in controlling gene expression. The findings provide new perspectives on the disease and its progression towards more severe forms.
The Mount Sinai Hospital has pioneered a new minimally invasive liver cancer treatment method that allows doctors to treat patients on more days of the week, improving access and reducing wait times. This breakthrough innovation, called TheraSphere Y-90 Any Day Dosing, enables flexible scheduling and seamless care coordination.
A study published in Nature Health reveals a strong link between pesticide exposure and the risk of developing certain cancers. The research shows that pesticide exposure increases the risk of cancer by 150% in areas with high levels of pollution, and highlights early biological effects before cancer develops.
Researchers found that the three-drug combination increased autophagosome formation and autophagic flux in uveal melanoma cells, killing them via enhanced autophagy. The study suggests a potential therapeutic approach for treating metastatic uveal melanoma, particularly in liver-targeted disease.
A new genetic 'roadmap' provides a navigational framework for more precise diagnosis and treatment of intrahepatic cholangiocarcinoma. The framework identifies five molecular subtypes, each associated with distinct therapeutic vulnerabilities, enabling targeted treatment strategies.
The BiliSeq test detected approximately 82% of bile duct cancers, compared to 44% with pathology alone, and increased cancer detection to nearly 90% when combined with pathology. This improved accuracy enables physicians to provide more personalized medicine and treatment options for patients.
Researchers developed a machine learning model that analyzes patient demographics, electronic health record data, and blood test results to predict hepatocellular carcinoma (HCC) risk. The model achieved high accuracy and outperformed existing liver cancer risk prediction models, offering potential for widespread use in resource-limite...
Researchers from Institute of Science Tokyo reveal the SPP1–CD44–Hedgehog signaling pathway as a key driver of fibrosis in liver tumors, hinting at its potential as a therapeutic target. The study provides valuable insights into how liver tumors actively shape their surroundings, driving the onset and progression of fibrosis.
A positive feedback loop between UBE2V1 and HIF-1α drives HCC progression by facilitating tumor growth and metastasis. UBE2V1 promotes HCC progression by competing with HIF-1α for VHL protein binding, leading to sustained HIF-1α stabilization.
Women with cardiometabolic risk factors such as type 2 diabetes and high waist circumference face a higher risk of liver fibrosis, with rates increasing 11-fold and 2.8-fold compared to men. The study highlights the importance of managing these risk factors for liver health beyond heart disease prevention.
Researchers found that quantifiable HBV RNA levels are associated with a significantly higher risk of HCC, independent of traditional risk factors. Chronic hepatitis B patients with concurrent liver dysfunction should be intensified under surveillance for HCC.
A study from The University of Osaka reveals a molecular pathway connecting liver congestion to liver fibrosis, portal hypertension, and liver tumorigenesis. Researchers identified increased activity of YAP and CTGF in liver sinusoidal endothelial cells as key molecules involved in this signaling pathway.
Researchers create detailed 3D reconstructions of human liver tissue, comparing healthy and cirrhotic livers, showing dysregulation of metabolite transport, reduced specialized cells, and disruption of vascular networks. The study highlights the importance of understanding organ structure for bioprinting artificial organs.
A study by RIKEN researchers identifies a MYCN-driven biomarker that predicts the risk of liver cancer. The biomarker, known as the MYCN niche score, uses machine learning to analyze gene expression patterns and indicates whether a tumor-free liver is at high risk for developing tumors.
Researchers at PolyU have identified a key driver of tumour growth in liver cancer and developed a monoclonal antibody that neutralises this protein. The antibody inhibits the growth and proliferation of FABP4-driven cancer stem cells, enhancing immune cell activity.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers uncover a hypoxia–m⁶A–Gal-1 regulatory axis that fuels HCC progression by stabilizing Galectin-1 (Gal-1) mRNA, promoting malignant phenotypes. Functional experiments confirmed Gal-1's role in enhancing HCC cell proliferation, migration, invasion, and EMT-driven phenotypic plasticity.
Ochsner MD Anderson is offering histotripsy, a revolutionary non-invasive treatment for liver tumors, approved by the FDA in 2023. The procedure uses ultrasound energy to destroy liver tumors in a single outpatient procedure.
The American Cancer Society's new 'Cancer Statistics, 2026' report reveals a historic milestone: US cancer survivorship has reached a record 70%, driven by major gains in cancers once considered difficult to treat. However, the report also highlights persistent disparities, concerning increases in cancer among women and younger adults.